This marks the company’s first major step in expanding its unique clinical trial delivery model across the globe
Care Access, the world leader in decentralized clinical trials delivery, today announced the acquisition of Instituto Brasil de Pesquisa Clínica (IBPClin), a clinical trial center in Rio de Janeiro, Brazil, as the first step to bring its decentralized clinical trial delivery model to Latin America, where hard-to-reach, underserved and traditionally underrepresented communities would gain unprecedented access to clinical trials.
Care Access has pioneered a unique clinical trial delivery model to decentralize the clinical research site and to take research to hard-to-reach patients, wherever they may be, through a combination of mobile research infrastructure, traveling clinical professionals, and virtual investigators. This approach has provided trial access for diverse and underserved communities across the United States, and has brought investment to healthcare infrastructure and increased the quality of care.
Over the last year, Care Access has made significant strides (leveraging Series C and Series D funding) to expand its capabilities for global clinical trials and the global regulatory ecosystem. The acquisition of IBPClin, one of the largest research centers in Latin America, is the first of many steps that Care Access is planning to announce that pave the path forward towards global decentralized trial delivery that reach more interested participants and achieve results on dramatically faster timelines.
“We’re on a path to achieve dramatically better and faster results for global clinical trials, with the intention to accelerate the approval process of new therapies and to bring more treatment options to healthcare. Our mission is to bring to life the future of clinical research, and IBPClin shares our vision to bring our unique DCT model to Latin America” said Ahmad Namvargolian, CEO and Co-Founder of Care Access. “A motivated world-class team, with the right level of support and the right resources, can make a dramatic impact – we look forward to seeing the fruits of this labor in the coming year.”
“Our industry is at a turning point as we build the infrastructure needed to bring potentially life-saving therapies and medicines to patients who otherwise wouldn’t have access,” said Dr. Luis Augusto Russo, co-CEO of IBPClin. “We know that, as part of Care Access, we will continue running clinical trials at the highest standards and then expand our opportunities, reach, and capabilities even further.”
IBPClin has conducted 160+ industry-sponsored research studies, enrolling over 7000 participants across 12 Brazilian states, and offers telemedicine, remote monitoring, and home care assistance for patients. Now, as part of Care Access, the research team can serve patients in Latin America with what has so far been US-only decentralized capabilities that can take complex research visits to any interested patient.
To learn more about how a decentralized approach can improve access to clinical trials and achieve results in dramatically faster timelines, contact trials@careaccess.com.
About Care Access
Care Access is a leading decentralized research organization (DRO) that breaks down traditional barriers in clinical research for patients, sponsors, and physicians. Its innovative model brings decentralized trials, Sites On Demand™, Virtual PIs, and Mobile Sites to previously unreachable patient populations to expand the impact of clinical research. Supported by top pharmaceutical and biotech partners across twenty different therapeutic areas, Care Access is scaling and globalizing its new model for clinical trial delivery, where more physicians and patients can engage in life-saving research to develop new therapies faster. To find out how Care Access is transforming the future of clinical trials, visit www.careaccess.com
About IBPClin
IBPClin is a Clinical Trial Center that has been involved in trials to develop new drugs for different diseases for over two decades. It specializes in running clinical trials on drugs in phases 2, 3 and 4. It partners with scientists from global and local pharmaceutical companies. Recently, it has been involved in studies on COVID, Cardiology, Endocrinology and Immunology. To find out more, please visit www.ibpclin.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220628006169/en/
Contacts
Alyssa Horowitz, media@careaccess.com
